Invention Grant
- Patent Title: N3-substituted iminopyrimidinones as antimalarial agents
-
Application No.: US16076400Application Date: 2017-02-13
-
Publication No.: US11766435B2Publication Date: 2023-09-26
- Inventor: Tanweer A. Khan , Jared N. Cumming , David B. Olsen , Justin A. Boddey , Alan F. Cowman , Brad E. Sleebs
- Applicant: Merck Sharp & Dohme LLC , The Walter and Eliza Hall Institute of Medical Research
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme LLC,The Walter and Eliza Hall Institute of Medical Research
- Current Assignee: Merck Sharp & Dohme LLC,The Walter and Eliza Hall Institute of Medical Research
- Current Assignee Address: US NJ Rahway; AU Victoria
- Agent Sylvia A. Ayler; Catherine D. Fitch
- International Application: PCT/US2017/017603 2017.02.13
- International Announcement: WO2017/142825A 2017.08.24
- Date entered country: 2018-08-08
- Main IPC: A61K31/4709
- IPC: A61K31/4709 ; A61K9/06 ; A61K47/10 ; A61K47/12 ; A61P17/10 ; A61P17/00 ; A61P17/04 ; A61P31/04 ; A61K31/513 ; A61P33/06 ; A61K31/527 ; A61K9/00 ; A61K45/06

Abstract:
The present invention provides methods of treating malaria comprising administration of an N3-substituted iminopyrimidinone of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables R1, R2, R3, R4, R5, A, B, L, m, and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
Public/Granted literature
- US20200230140A1 N3-SUBSTITUTED IMINOPYRIMIDINONES AS ANTIMALARIAL AGENTS Public/Granted day:2020-07-23
Information query
IPC分类: